Early oncology focus Medelis specializes in preclinical and phase 1 through phase 3 oncology trials across North America and Europe, offering depth in immunotherapy and complex oncology programs. This presents an opportunity to expand sponsor pipelines seeking CROs with proven oncology leadership and end-to-end trial execution in early to mid-phase studies.

Global expansion potential With existing operations across North America and Europe and a history of growth through brand integration, Medelis can help multinational sponsors consolidate CRO partners for global trial execution, reducing vendor fragmentation and accelerating timelines.

Strategic partnerships Participation in major industry events such as BIO Europe and ASCO indicates proactive visibility to biopharma sponsors; sales outreach can leverage conference relationships, speaking engagements, and sponsor matchmaking to position Medelis as a preferred oncology CRO for early-to-mid phase programs.

Focused capacity fit Medelis operates with a lean team (11-50 employees) yet delivers specialized oncology expertise, suggesting a strong fit for mid-sized sponsors needing nimble, specialized execution without the footprint of large CROs, opening opportunities in mid-size biotech and specialty pharma.

Financial credibility Reported revenue in the range of 25 to 50 million positions Medelis as a credible partner for sponsors seeking established CROs with proven capabilities in oncology trials, enabling a conversation around scalable resource allocation, risk sharing, and phased growth collaborations.